Compound: MELANOSTATIN
SMILES: O=C(N[C@H](C(=O)NCC(=O)N)CC(C)C)[C@H]1NCCC1
InChIKey: NOOJLZTTWSNHOX-UWVGGRQHSA-N
Synonyms: MELANOSTATIN, MIF-I, MIF-1, H-Pro-Leu-Gly-NH2, Pro-Leu-Gly-NH2, (2S)-N-[(2S)-1-[(2-amino-2-oxoethyl)amino]-4-methyl-1-oxopentan-2-yl]pyrrolidine-2-carboxamide, prolylleucylglycinamide, (2S)-N-(carbamoylmethyl)-4-methyl-2-[(2S)-pyrrolidin-2-ylformamido]pentanamide, Pro-Leu-Glyamide, Prol Leu Gly NH2, Prol-Leu-Gly-NH2, Oxytocin (7-9), Prolyl Leucyl Glycinamide, (2S)-N-(carbamoylmethyl)-4-methyl-2-((2S)-pyrrolidin-2-ylformamido)pentanamide, DTXSID801054365, (2S)-N-((2S)-1-((2-amino-2-oxoethyl)amino)-4-methyl-1-oxopentan-2-yl)pyrrolidine-2-carboxamide, RefChem:925443, 4J2YQP4NA3, 9083-38-9, MSH release-inhibiting factor, Prolyl-Leucyl-Glycinamide, 2002-44-0, L-Prolyl-L-leucylglycinamide, Oxytocin C-terminal tripeptide, (S)-N-((S)-1-((2-Amino-2-oxoethyl)amino)-4-methyl-1-oxopentan-2-yl)pyrrolidine-2-carboxamide, 7-9-Oxytocin, Melanostatin I (ox), MSH-release inhibiting factor I, Prolylleucylglycine amide, L-Prolyl-L-leucylglycylamide, Glycinamide, L-prolyl-L-leucyl-, L-Proline-L-leucine-glycine-amide, MFCD00037866, CHEMBL317488, 3KY24B4Q62, (2S)-N-(carbamoylmethyl)-4-methyl-2-{[(2S)-pyrrolidin-2-yl]formamido}pentanamide, Pro-Leu-Gly amide, UNII-3KY24B4Q62, Prolyl-L-leucyl-glycinamide, L-, EINECS 217-902-7, L-pro-L-leu-gly-NH2, MELANOSTATIN MIF-I, orb525682, SCHEMBL362530, MELANOSTATIN MIF-I [MI], DTXSID20173841, CHEBI:168693, NOOJLZTTWSNHOX-UWVGGRQHSA-N, GLXC-23941, MIF-I, (-)-, BBL033793, BDBM50060601, EX-A15816, HB1874, MFCD08282654, STL372235, 2-Pyrrolidinecarboxamide, N-(1-((carbamoylmethyl)carbamoyl)-3-methylbutyl)-, AKOS015955826, MSH RELEASE-INHIBITING FACTOR I, DA-66890, FM109235, NS-04720, PD070730, HY-107663, CS-0029128, NS00026500, EN300-302728, 6-((E)-3-Oxo-3-phenyl-propenyl)-1H-pyrimidine-2,4-dione, (E)-6-(3-oxo-3-phenylprop-1-enyl)pyrimidine-2,4(1H,3H)-dione, (2S)-N-[(1S)-1-[(2-amino-2-oxo-ethyl)carbamoyl]-3-methyl-butyl]pyrrolidine-2-carboxamide, (S)-Pyrrolidine-2-carboxylic acid [(S)-1-(carbamoylmethyl-carbamoyl)-3-methyl-butyl]-amide, Pyrrolidine-2-carboxylic acid [1-(carbamoylmethyl-carbamoyl)-3-methyl-butyl]-amide
Theoretical properties:
molecular_formula: C13H24N4O3
molecular_weight: 284.35 g/mol
exact_mass: 284.18484064 g/mol
formal_charge: 0
hydrogen_bond_donor_count: 4
hydrogen_bond_acceptor_count: 4
rotatable_bond_count: 7
heavy_atom_count: 20
topological_polar_surface_area: 113 Å²
isotope_atom_count: 0
covalently_bonded_unit_count: 1
Physical properties:
Descriptions:
pubchem: Melanostatin is an oligopeptide.
chembl: Unnamed Compound is a protein listed in the ChEMBL database but has not progressed to an approved clinical phase.
wikipedia: Melanocyte-inhibiting factor (also known as Pro-Leu-Gly-NH2, melanostatin, MSH release–inhibiting hormone, or MIF-1) is an endogenous peptide fragment derived from cleavage of the hormone oxytocin, but having generally different actions in the body. MIF-1 produces multiple effects, both blocking the effects of opioid receptor activation, while at the same time acting as a positive allosteric modulator of the D2 and D4 dopamine receptor subtypes, as well as inhibiting release of other neuropeptides such as alpha-MSH, and potentiating melatonin activity.
This complex mix of actions produces a profile of antidepressant, nootropic, and anti-Parkinsonian effects when MIF-1 is administered, and it has been investigated for various medical uses. MIF-1 is unusually resistant to metabolism in the bloodstream, and crosses the blood–brain barrier easily, though it is poorly active orally and is usually injected. Several other closely related peptides with important actions in the body include Tyr-MIF-1 and endomorphin-1 and -2.